Insider Selling: Natera (NASDAQ:NTRA) Insider Sells $335,091.68 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,652 shares of Natera stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $202.84, for a total value of $335,091.68. Following the transaction, the insider owned 140,643 shares of the company’s stock, valued at $28,528,026.12. This represents a 1.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Friday, May 1st, Solomon Moshkevich sold 3,405 shares of Natera stock. The stock was sold at an average price of $203.69, for a total value of $693,564.45.
• On Monday, April 27th, Solomon Moshkevich sold 2,182 shares of Natera stock. The stock was sold at an average price of $204.10, for a total value of $445,346.20.
• On Wednesday, April 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $202.30, for a total value of $606,900.00.
• On Tuesday, March 10th, Solomon Moshkevich sold 915 shares of Natera stock. The stock was sold at an average price of $204.13, for a total value of $186,778.95.
• On Monday, March 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $199.85, for a total value of $599,550.00.

Natera Price Performance

Shares of Natera stock opened at $223.37 on Friday. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $256.36. The company has a market capitalization of $31.99 billion, a P/E ratio of -137.04 and a beta of 1.57. The business has a 50 day moving average price of $202.37 and a 200 day moving average price of $215.69.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.81. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.The firm had revenue of $665.50 million during the quarter, compared to the consensus estimate of $600.68 million. During the same period in the previous year, the firm posted ($0.41) EPS. As a group, research analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Institutional Trading of Natera

Institutional investors have recently made changes to their positions in the stock. Integrated Wealth Concepts LLC boosted its position in Natera by 6.6% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after purchasing an additional 96 shares during the period. NewEdge Advisors LLC lifted its holdings in Natera by 68.3% in the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after buying an additional 1,847 shares in the last quarter. Focus Partners Wealth lifted its holdings in Natera by 8.6% in the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after buying an additional 474 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in Natera in the 2nd quarter worth $298,000. Finally, WINTON GROUP Ltd acquired a new position in Natera in the 2nd quarter worth $558,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced a new collaboration with Diakonos Oncology to use Signatera in a Phase I/II study for refractory melanoma, expanding a key cancer-testing product into another clinical use case and reinforcing its oncology growth story. Article Title
• Positive Sentiment: Canaccord raised its price target on Natera to $250 from $200, signaling stronger confidence in the company’s outlook and helping fuel bullish sentiment. Article Title
• Positive Sentiment: Natera is also drawing attention from investors after commentary calling it a favorite stock idea for the rest of 2026, which adds to the momentum around the name. Article Title

Analyst Upgrades and Downgrades

NTRA has been the subject of several recent analyst reports. William Blair initiated coverage on shares of Natera in a research note on Tuesday, April 14th. They issued an “outperform” rating for the company. Wall Street Zen cut shares of Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Morgan Stanley lowered their target price on shares of Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, March 3rd. Piper Sandler reaffirmed an “overweight” rating and issued a $249.00 target price on shares of Natera in a research note on Tuesday, May 12th. Finally, Evercore reaffirmed an “outperform” rating and issued a $270.00 target price on shares of Natera in a research note on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $256.60.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.